Stay updated with breaking news from Negative Symptom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations.
Acadia Pharmaceuticals decided to stop conducting further clinical trials with pimavanserin for negative symptoms of negative due to topline results.
Shares of ACADIA Pharmaceuticals Inc. (ACAD) are down more than 18 percent in pre-market on Tuesday at $19.71, after its schizophrenia drug candidate failed to meet the primary endpoint in late-stage study.
Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.
The 26-week ADVANCE-2 study included 545 adults with predominant negative symptoms of schizophrenia who were currently receiving antipsychotic treatment and achieved control of positive symptoms.